Northwest Biotherapeutics (OTCMKTS:NWBO) has made its name as a biotech company that is involved in the development of personalised therapies meant for treating tumour related cancers. The company is best known for having developed the product DCVax, which is meant for treating tumour related cancers.


Over the course of the past few weeks, the Northwest stock has been in consolidation mode and that is usually an indication of a possible breakout. In this regard, it might be a good move to take a look at a key announcement from the company earlier on this month. Back on March 17, the company announced that the production capacity related work at its advanced manufacturing plant located in Sawston, United Kingdom had been completed.

It is a significant boost for the company and Northwest added that it is now in the last stages of preparing the application to the certificate from UK Medicines and Health Products Regulatory Authority. At this point in time, Northwest has been producing its dendritic cell products from a clean room plant located in London, United Kingdom.

ECGI Holdings Closed January with a Strong Strategic Move to Conquer the Cannabis Market in California

That particular facility can produce enough for four to six patients each month. However, the Sawston facility is a different kettle of fish altogether. The facility has two floors and the total area spans as much as 88345 square feet.

The facility is going to have a pair of manufacturing areas, which are going to take up as much as 4400 square feet in the ground floor. However, the most important thing with regards to the Sawston facility is the fact that the Northwest’s production capabilities are going to be boosted significantly.

The plant is going to have considerable storage space and with two manufacturing areas running at full tilt, the company will be able to product enough medicines for 40 to 45 patients in a month. That reflects a massive jump from the present levels and is expected to come as a big boost to Northwest.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.